Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26004429 | 1.00 | SIGMAR1 (0.46) | SIGMAR1OPRM1OPRK1EBPSLC18A3 | |
| SCHEMBL25361889 | 1.00 | SIGMAR1 (0.46) | SIGMAR1OPRM1OPRK1EBPSLC18A3 | |
| SCHEMBL26004590 | 0.86 | SIGMAR1 (0.46) | SIGMAR1OPRM1OPRK1EBPSLC18A3 | |
| SCHEMBL26014956 | 0.85 | SIGMAR1 (0.46) | SIGMAR1OPRM1OPRK1EBPSLC18A3 | |
| SCHEMBL26004354 | 0.84 | SIGMAR1 (0.49) | SIGMAR1PRCP | |
| SCHEMBL26013277 | 0.84 | SIGMAR1 (0.41) | SIGMAR1OPRM1OPRK1PRCPOPRD1 | |
| SCHEMBL26004428 | 0.84 | SIGMAR1 (0.48) | SIGMAR1OPRM1OPRK1OPRD1 | |
| SCHEMBL26013583 | 0.83 | SIGMAR1 (0.46) | SIGMAR1OPRM1PRCPOPRD1 | |
| SCHEMBL26004667 | 0.82 | SIGMAR1 (0.45) | SIGMAR1PRCP | |
| SCHEMBL26014541 | 0.82 | SIGMAR1 (0.45) | SIGMAR1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |